http://clinicaloptions.com/Oncology.aspx New treatment data and educational activities for Oncology and Hematology Clinicians en-us http://images.imedoptions.com/img.asp?img=cco/CCO_ONC_RSS.gif http://clinicaloptions.com/oncology http://clinicaloptions.com/Oncology/Treatment%20Updates/Pathways/Modules/Multikinase%20Inhibitors.aspx Lee S. Rosen, MD, discusses the central role VEGF plays in tumor angiogenesis, and how this and additional targets have been exploited in the development of tyrosine kinase inhibitors. http://clinicaloptions.com/Oncology/Treatment%20Updates/IPCU2007/Modules/Risk%20Stratification.aspx Daniel P. Petrylak, MD, reviews current data on risk stratification and clinical management of high-risk patients presented at the 17th International Prostate Cancer Update meeting held in Vail, Colorado. http://clinicaloptions.com/Oncology/Treatment%20Updates/Prostate%20Cancer%202007/Modules/Managing%20Complications.aspx James A. Eastham, MD, reviews new techniques and management options for disease and treatment-related complications presented at the 2007 International Prostate Cancer Update held in Vail, Colorado. http://clinicaloptions.com/Oncology/Treatment%20Updates/IPCU2007/Modules/Advanced%20Disease.aspx Nicholas J. Vogelzang, MD, reviews data on treating advanced or hormone-refractory prostate cancer presented at the 2007 International Prostate Cancer Update meeting held in Vail, Colorado. http://clinicaloptions.com/Oncology/Treatment%20Updates/IPCU2007/Modules/Localized%20Disease.aspx Mack Roach III, MD, reviews current data on the treatment of localized disease presented at the 2007 International Prostate Cancer Update meeting held in Vail, Colorado. http://clinicaloptions.com/Oncology/Treatment%20Updates/IPCU2007/Modules/Complementary%20Alternative%20Medicine.aspx Mark A. Moyad, MD, MPH, reviews current data on the use of complementary and alternative therapies in the treatment of high-risk patients with prostate cancer, which were presented at the 17th International Prostate Cancer Update meeting in Vail, Colorado. http://clinicaloptions.com/Oncology/Treatment%20Updates/IPCU2007/Modules/Screening%20and%20Prevention.aspx Per-Anders Abrahamsson, MD, PhD, reviews current data on the epidemiology, screening, prevention, and biomarkers associated with prostate cancer presented at the 2007 International Prostate Cancer Update meeting held in Vail, Colorado. http://clinicaloptions.com/Oncology/Conference%20Coverage/Prostate%202007.aspx Anthony DAmico, MD, PhD; Daniel P. Petrylak, MD; and Nicholas J. Vogelzang, MD, review the most significant prostate cancer data and its clinical implications on improving patient outcomes. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Tracks/Prostate/Prostate%20Cancer.aspx E. David Crawford, MD, Philip Kantoff, MD, Nicholas J. Vogelzang, MD, and David I. Quinn, MD, PhD, review data from recent studies regarding the treatment of prostate cancer. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Capsules/4568.aspx?Track=Prostate CCO Oncology - In a retrospective analysis of men who experienced disease recurrence following radical prostatectomy, PSA doubling time less than 3 months predicts for those at greatest risk for prostate cancerspecific death. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Capsules/4562.aspx?Track=Prostate CCO Oncology - In a preliminary, randomized double-blind placebo-controlled trial, imatinib does not influence docetaxel activity in androgen-independent prostate cancer patients with bone metastases. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Capsules/4558.aspx?Track=Prostate CCO Oncology - A randomized, phase II trial demonstrates that a nontaxane-based regimen has limited efficacy and increased toxicity in taxane-resistant, hormone-refractory prostate cancer patients. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Capsules/4517.aspx?Track=Prostate CCO Oncology - Preliminary results from SWOG 9346 demonstrate that absolute PSA level after 7 months of androgen deprivation therapy in men with newly diagnosed metastatic prostate cancer predicts survival outcome. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Capsules/4515.aspx?Track=Prostate CCO Oncology - Randomized study data indicate that single-dose zoledronic acid preserves and improves bone mineral density in prostate cancer patients currently taking GnRH agonists. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Capsules/4516.aspx?Track=Prostate CCO Oncology - Retrospective study demonstrates that pain responses may be associated with PSA levels and may be predictive of survival in metastatic, hormone-refractory prostate cancer patients. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Capsules/4500.aspx?Track=Prostate CCO Oncology - The novel agent MLN2704 that targets prostate-specific membrane antigen is both safe and effective in patients with metastatic castration-resistant prostate cancer. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/Capsules/4514.aspx?Track=Prostate CCO Oncology - A recently developed nomogram is capable of accurately predicting 6-year probability of progression-free survival after salvage radiotherapy in prostate cancer patients with postsurgical biochemical recurrence. http://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Oncology%20June%202006/News/News_2501.aspx CCO Oncology - In a randomized, double-blind, controlled phase II trial, the administration of a dual-vector prostate cancer vaccine, PROSTVAC-VF, combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), has demonstrated no improvement in progression-free survival compared with placebo in patients with hormone-refractory prostate cancer, according to data presented at the 42nd Annual Meeting of the American Society for Clinical Oncology in Atlanta, Georgia. http://clinicaloptions.com/Oncology/Resources/News%20and%20Comment/Articles/news_imed_170.aspx CCO Oncology - Researchers at the National Cancer Institute have developed a new statistical model that provides improved estimates of survival outcomes for newly diagnosed cancer patients, according to a recently published study in the journal Cancer. http://clinicaloptions.com/Oncology/Conference%20Coverage/San%20Francisco%202006/Tracks/Conference%20Report/Conference%20Report.aspx CCO Oncology - Tomasz M. Beer, MD, and James A. Eastham, MD, review clinical data regarding the utility of chemotherapy in the treatment of prostate cancer.